Zavicefta

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

avibactam sodium, ceftazidime pentahydrate

Available from:

Pfizer Ireland Pharmaceuticals

ATC code:

J01

INN (International Name):

ceftazidime, avibactam

Therapeutic group:

Antibakterijski lijekovi za sistemsku primjenu,

Therapeutic area:

Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections

Therapeutic indications:

Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

2016-06-23

Patient Information leaflet

                                30
B. UPUTA O LIJEKU
31
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
ZAVICEFTA 2 G/0,5 G PRAŠAK ZA KONCENTRAT ZA OTOPINU ZA INFUZIJU
ceftazidim/avibaktam
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili medicinskoj
sestri.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili medicinsku sestru. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Zavicefta i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati lijek Zavicefta
3.
Kako primjenjivati lijek Zavicefta
4.
Moguće nuspojave
5.
Kako čuvati lijek Zavicefta
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ZAVICEFTA I ZA ŠTO SE KORISTI
ŠTO JE ZAVICEFTA
Zavicefta je antibiotik koji sadrži dvije djelatne tvari –
ceftazidim i avibaktam.

Ceftazidim pripada skupini antibiotika koji se zovu "cefalosporini".
Može uništiti brojne vrste
bakterija.

Avibaktam je "inhibitor beta-laktamaza" koji pomaže ceftazidimu
uništiti neke bakterije koje
ceftazidim ne može uništiti sam.
ZA ŠTO SE ZAVICEFTA KORISTI
Zavicefta se koristi u odraslih osoba i pedijatrijskih bolesnika u
dobi od 3 mjeseca i starijih za
liječenje:

infekcija u trbušnoj šupljini (abdomenu)

infekcija mokraćnog mjehura ili bubrega, koje se zovu "infekcije
mokraćnog sustava"

infekcije pluća koja se zove "pneumonija"

infekcija uzrokovanih bakterijama koje drugi antibiotici možda ne
mogu uništiti
Zavicefta se koristi u odraslih osoba za liječenje infekcije krvi
povezane s infekcijama u trbuhu,
mokraćnim putevima ili upalom pluća.
KAKO ZAVICEFTA DJELUJE
Zavicefta djeluje tako da ubija određene vrste bakterija koje mogu
uzrokovati ozbiljne infekcije.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI LIJEK ZAVICEFTA
NEMOJTE PRIMJENJIVATI LIJEK ZAVICEFTA:

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Zavicefta 2 g/0,5 g prašak za koncentrat za otopinu za infuziju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna bočica sadrži 2 g ceftazidima u obliku ceftazidim pentahidrata
te 0,5 g avibaktama u obliku
avibaktamnatrija.
Nakon rekonstitucije, 1 ml otopine sadrži 167,3 mg ceftazidima i 41,8
mg avibaktama (vidjeti dio 6.6).
Pomoćna tvar s poznatim učinkom:
Zavicefta sadrži približno 146 mg natrija po bočici.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Prašak za koncentrat za otopinu za infuziju (prašak za koncentrat).
Prašak bijele do žute boje.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Zavicefta je indicirana u odraslih osoba i pedijatrijskih bolesnika u
dobi od 3 mjeseca i starijih za
liječenje sljedećih infekcija (vidjeti dijelove 4.4 i 5.1):

komplicirane intraabdominalne infekcije

komplicirane infekcije mokraćnog sustava, uključujući
pijelonefritis

bolnička pneumonija, uključujući pneumoniju povezanu s mehaničkom
ventilacijom
Liječenje odraslih bolesnika s bakterijemijom koja je povezana ili se
sumnja da je povezana s bilo
kojom od gore navedenih infekcija.
Zavicefta je također indicirana za liječenje infekcija uzrokovanih
aerobnim Gram-negativnim
organizmima u odraslih osoba i pedijatrijskih bolesnika u dobi od 3
mjeseca i starijih s ograničenim
mogućnostima liječenja (vidjeti dijelove 4.2, 4.4 i 5.1).
Potrebno je uzeti u obzir službene smjernice o primjerenoj uporabi
antibakterijskih lijekova.
4.2
DOZIRANJE I NAČIN PRIMJENE
Preporučuje se koristiti lijek Zavicefta za liječenje infekcija
uzrokovanih aerobnim Gram-negativnim
organizmima u odraslih osoba i pedijatrijskih bolesnika u dobi od 3
mjeseca i starijih s ograničenim
mogućnostima liječenja tek nakon savjetovanja s liječnikom koji ima
odgovarajuće iskustvo u
liječenju infektivnih bolesti (vidjeti dio 4.4).
3
Doziranje
_Doza za odrasle osobe s klirensom kreatinina > 50 ml/min_
U tablici 1 prikazane su preporučene 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-02-2024
Public Assessment Report Public Assessment Report Bulgarian 20-11-2020
Patient Information leaflet Patient Information leaflet Spanish 20-02-2024
Public Assessment Report Public Assessment Report Spanish 20-11-2020
Patient Information leaflet Patient Information leaflet Czech 20-02-2024
Public Assessment Report Public Assessment Report Czech 20-11-2020
Patient Information leaflet Patient Information leaflet Danish 20-02-2024
Public Assessment Report Public Assessment Report Danish 20-11-2020
Patient Information leaflet Patient Information leaflet German 20-02-2024
Public Assessment Report Public Assessment Report German 20-11-2020
Patient Information leaflet Patient Information leaflet Estonian 20-02-2024
Public Assessment Report Public Assessment Report Estonian 20-11-2020
Patient Information leaflet Patient Information leaflet Greek 20-02-2024
Public Assessment Report Public Assessment Report Greek 20-11-2020
Patient Information leaflet Patient Information leaflet English 20-02-2024
Public Assessment Report Public Assessment Report English 20-11-2020
Patient Information leaflet Patient Information leaflet French 20-02-2024
Public Assessment Report Public Assessment Report French 20-11-2020
Patient Information leaflet Patient Information leaflet Italian 20-02-2024
Public Assessment Report Public Assessment Report Italian 20-11-2020
Patient Information leaflet Patient Information leaflet Latvian 20-02-2024
Public Assessment Report Public Assessment Report Latvian 20-11-2020
Patient Information leaflet Patient Information leaflet Lithuanian 20-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-02-2024
Public Assessment Report Public Assessment Report Lithuanian 20-11-2020
Patient Information leaflet Patient Information leaflet Hungarian 20-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 20-02-2024
Public Assessment Report Public Assessment Report Hungarian 20-11-2020
Patient Information leaflet Patient Information leaflet Maltese 20-02-2024
Public Assessment Report Public Assessment Report Maltese 20-11-2020
Patient Information leaflet Patient Information leaflet Dutch 20-02-2024
Public Assessment Report Public Assessment Report Dutch 20-11-2020
Patient Information leaflet Patient Information leaflet Polish 20-02-2024
Public Assessment Report Public Assessment Report Polish 20-11-2020
Patient Information leaflet Patient Information leaflet Portuguese 20-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 20-02-2024
Public Assessment Report Public Assessment Report Portuguese 20-11-2020
Patient Information leaflet Patient Information leaflet Romanian 20-02-2024
Public Assessment Report Public Assessment Report Romanian 20-11-2020
Patient Information leaflet Patient Information leaflet Slovak 20-02-2024
Public Assessment Report Public Assessment Report Slovak 20-11-2020
Patient Information leaflet Patient Information leaflet Slovenian 20-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 20-02-2024
Public Assessment Report Public Assessment Report Slovenian 20-11-2020
Patient Information leaflet Patient Information leaflet Finnish 20-02-2024
Public Assessment Report Public Assessment Report Finnish 20-11-2020
Patient Information leaflet Patient Information leaflet Swedish 20-02-2024
Public Assessment Report Public Assessment Report Swedish 20-11-2020
Patient Information leaflet Patient Information leaflet Norwegian 20-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 20-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 20-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 20-02-2024

View documents history